{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_7144", "batch_size": 200, "batch_pos": 85, "statement_text": "It is too early to tell how many doses Moderna will be able to manufacture, said Robert Johnson, director of the medical countermeasures program at HHS, on the call.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment discusses manufacturing capacity factually, lacking high-potency framing.", "method": "llm_batch", "batch_id": "batch_2_8916", "batch_size": 200, "batch_pos": 52, "statement_text": "It is too early to tell how many doses Moderna will be able to manufacture, said Robert Johnson, director of the medical countermeasures program at HHS, on the call.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "No moderate verbs paired with scale/impact information.", "method": "llm_batch", "batch_id": "batch_3_21352", "batch_size": 200, "batch_pos": 1, "statement_text": "It is too early to tell how many doses Moderna will be able to manufacture, said Robert Johnson, director of the medical countermeasures program at HHS, on the call.", "article_id": 1745}
